SK285408B6 - Analógy rapamycínu obsahujúce tetrazol so skrátenými polčasmi a ich použitie - Google Patents

Analógy rapamycínu obsahujúce tetrazol so skrátenými polčasmi a ich použitie Download PDF

Info

Publication number: SK285408B6
Authority: SK; Slovakia
Prior art keywords: compounds; rapamycin; diseases; compound; agents
Prior art date: 1997-09-26

Application number

SK417-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK4172000A3 (en

Inventor

Karl W. Mollison

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-26

Filing date

1998-09-24

Publication date

2007-01-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285408(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-24 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2000-08-14 Publication of SK4172000A3 publication Critical patent/SK4172000A3/sk

2007-01-04 Publication of SK285408B6 publication Critical patent/SK285408B6/sk

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims description 31
150000003839 salts Chemical class 0.000 claims abstract description 4
-1 C-31 hydroxyl group ester Chemical class 0.000 claims description 16
150000002148 esters Chemical class 0.000 claims description 3
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
125000005633 phthalidyl group Chemical group 0.000 claims description 2
150000001875 compounds Chemical class 0.000 abstract description 73
239000000203 mixture Substances 0.000 abstract description 25
239000003814 drug Substances 0.000 abstract description 20
238000011282 treatment Methods 0.000 abstract description 14
230000002401 inhibitory effect Effects 0.000 abstract description 9
208000023275 Autoimmune disease Diseases 0.000 abstract description 7
241000124008 Mammalia Species 0.000 abstract description 7
230000000694 effects Effects 0.000 abstract description 7
230000002519 immonomodulatory effect Effects 0.000 abstract description 7
208000037803 restenosis Diseases 0.000 abstract description 7
206010028980 Neoplasm Diseases 0.000 abstract description 6
201000011510 cancer Diseases 0.000 abstract description 5
230000002538 fungal effect Effects 0.000 abstract description 4
208000026278 immune system disease Diseases 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract description 3
229960002930 sirolimus Drugs 0.000 description 27
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
201000010099 disease Diseases 0.000 description 16
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
229940079593 drug Drugs 0.000 description 14
238000000034 method Methods 0.000 description 14
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
239000000651 prodrug Substances 0.000 description 11
229940002612 prodrug Drugs 0.000 description 11
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
229960001967 tacrolimus Drugs 0.000 description 9
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 9
238000002054 transplantation Methods 0.000 description 9
239000003018 immunosuppressive agent Substances 0.000 description 8
239000007787 solid Substances 0.000 description 8
208000006673 asthma Diseases 0.000 description 7
210000001508 eye Anatomy 0.000 description 7
230000001506 immunosuppresive effect Effects 0.000 description 7
239000002502 liposome Substances 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
108010036949 Cyclosporine Proteins 0.000 description 5
201000004624 Dermatitis Diseases 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000002245 particle Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
229930105110 Cyclosporin A Natural products 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
229960001265 ciclosporin Drugs 0.000 description 4
210000004087 cornea Anatomy 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
229960003444 immunosuppressant agent Drugs 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
125000003831 tetrazolyl group Chemical group 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
208000009137 Behcet syndrome Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
206010029240 Neuritis Diseases 0.000 description 3
208000031481 Pathologic Constriction Diseases 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229940125721 immunosuppressive agent Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
206010023332 keratitis Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000002678 macrocyclic compounds Chemical class 0.000 description 3
239000003120 macrolide antibiotic agent Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000036262 stenosis Effects 0.000 description 3
208000037804 stenosis Diseases 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
208000032467 Aplastic anaemia Diseases 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000006069 Corneal Opacity Diseases 0.000 description 2
206010011831 Cytomegalovirus infection Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010019663 Hepatic failure Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
201000002287 Keratoconus Diseases 0.000 description 2
241001123008 Leukoma Species 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000031709 Skin Manifestations Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
239000003906 humectant Substances 0.000 description 2
230000003463 hyperproliferative effect Effects 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
208000007903 liver failure Diseases 0.000 description 2
231100000835 liver failure Toxicity 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
UBQBKOBGHRTZRG-UPAXIQFWSA-N 104987-09-9 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 UBQBKOBGHRTZRG-UPAXIQFWSA-N 0.000 description 1
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
AOPMJTXVTVQAGD-KNLBXDFQSA-N 5,6,8,11,12,13,14,15,16,17,18,19,23,24,25,25a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-15,19-epoxy-1h,3h-pyrrolo(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h)-tetrone Chemical compound C1CC(O)C(OC)CC1\C=C(/C)C1C(C)C(O)CC(=O)C(CC=C)\C=C(C)/CC(C)CC(OC)C(C(CC2C)OC)OC2(O)C(=O)C(=O)N2CCCC2C(=O)O1 AOPMJTXVTVQAGD-KNLBXDFQSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
208000007788 Acute Liver Failure Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002065 Anaemia megaloblastic Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
206010002921 Aortitis Diseases 0.000 description 1
206010002961 Aplasia Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
102000004631 Calcineurin Human genes 0.000 description 1
108010042955 Calcineurin Proteins 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
206010009657 Clostridium difficile colitis Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101100456320 Homo sapiens NR3C2 gene Proteins 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010021074 Hypoplastic anaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
206010024380 Leukoderma Diseases 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000000682 Megaloblastic Anemia Diseases 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010051606 Necrotising colitis Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000027771 Obstructive airways disease Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
206010060932 Postoperative adhesion Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
206010037128 Pseudomembranous colitis Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
231100000579 Toxinosis Toxicity 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047295 Ventricular hypertrophy Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
206010000496 acne Diseases 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000003915 air pollution Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
ZDQSOHOQTUFQEM-NURRSENYSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-NURRSENYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
229960004360 azathioprine sodium Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
239000012267 brine Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000003683 cardiac damage Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
210000004268 dentin Anatomy 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
210000000918 epididymis Anatomy 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
210000000720 eyelash Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
230000009795 fibrotic process Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical group [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960002706 gusperimus Drugs 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000023569 ischemic bowel disease Diseases 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
231100000149 liver necrosis Toxicity 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000013521 mastic Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
231100001016 megaloblastic anemia Toxicity 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
208000004995 necrotizing enterocolitis Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000002304 perfume Substances 0.000 description 1
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
210000004261 periodontium Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000003658 preventing hair loss Effects 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
229940072288 prograf Drugs 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229940099538 rapamune Drugs 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
230000037390 scarring Effects 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000027849 smooth muscle hyperplasia Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
WISNYKIQFMKSDQ-UHFFFAOYSA-N sodium;6-(3-methyl-5-nitroimidazol-4-yl)sulfanylpurin-9-ide Chemical compound [Na+].CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1[N-]C=N2 WISNYKIQFMKSDQ-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000005671 trienes Chemical class 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SK417-2000A 1997-09-26 1998-09-24 Analógy rapamycínu obsahujúce tetrazol so skrátenými polčasmi a ich použitie SK285408B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93814497A	1997-09-26	1997-09-26
PCT/US1998/020111 WO1999015530A1 (fr)	1997-09-26	1998-09-24	Analogues de rapamycine contenant du tetrazole a demi-vies raccourcies

Publications (2)

Publication Number	Publication Date
SK4172000A3 SK4172000A3 (en)	2000-08-14
SK285408B6 true SK285408B6 (sk)	2007-01-04

Family

ID=25470968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK417-2000A SK285408B6 (sk)	1997-09-26	1998-09-24	Analógy rapamycínu obsahujúce tetrazol so skrátenými polčasmi a ich použitie

Country Status (27)

Country	Link
EP (1)	EP1015459B9 (fr)
JP (1)	JP3790424B2 (fr)
KR (3)	KR100833812B1 (fr)
CN (1)	CN1161360C (fr)
AR (1)	AR015940A1 (fr)
AT (1)	ATE297398T1 (fr)
AU (1)	AU745576B2 (fr)
BG (1)	BG64955B1 (fr)
BR (1)	BR9812305A (fr)
CA (1)	CA2303934C (fr)
CO (1)	CO5070656A1 (fr)
CZ (1)	CZ299365B6 (fr)
DE (1)	DE69830502T2 (fr)
DK (1)	DK1015459T3 (fr)
ES (1)	ES2244087T3 (fr)
HU (1)	HU228368B1 (fr)
IL (2)	IL134607A0 (fr)
NO (1)	NO325813B1 (fr)
NZ (2)	NZ502896A (fr)
PL (1)	PL191212B1 (fr)
PT (1)	PT1015459E (fr)
SI (1)	SI1015459T1 (fr)
SK (1)	SK285408B6 (fr)
TR (1)	TR200000778T2 (fr)
TW (1)	TW557297B (fr)
WO (1)	WO1999015530A1 (fr)
ZA (1)	ZA988750B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399480B2 (en)	1997-09-26	2008-07-15	Abbott Laboratories	Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US7357942B2 (en) *	1997-09-26	2008-04-15	Abbott Laboratories	Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en)	1998-09-24	2011-06-14	Abbott Laboratories	Compounds and methods for treatment and prevention of diseases
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
DE60310383T2 (de) *	2002-01-29	2007-09-20	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Vorbeugung von gewebeadhäsion
US20030176455A1 (en) *	2002-03-13	2003-09-18	Wyeth	Method of inhibiting cell death
PL372103A1 (en)	2002-05-16	2005-07-11	Novartis Ag	Use of edg receptor binding agents in cancer
EP1511473B8 (fr)	2002-05-27	2013-07-24	Novartis AG	Alcanols bi-aromatiques
EP2263709A1 (fr) *	2002-09-06	2010-12-22	Abbott Laboratories	Dispositif médical doté d'un inhibiteur de l'hydratation
KR20080103117A (ko)	2002-09-24	2008-11-26	노파르티스 아게	탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
BRPI0410439A (pt)	2003-05-19	2006-06-06	Irm Llc	compostos e composições imunossupressoras
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
WO2006115509A2 (fr)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
KR20070070184A (ko)	2004-10-28	2007-07-03	와이어쓰	자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
WO2007011708A2 (fr)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Stent a revetement polymere renfermant de la rapamycine amorphe
WO2007011707A2 (fr)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
HRP20140338T1 (hr)	2005-07-25	2014-06-20	Emergent Product Development Seattle, Llc	Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP5164167B2 (ja)	2005-08-30	2013-03-13	ユニバーシティーオブマイアミ	免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
JP2009514870A (ja)	2005-11-04	2009-04-09	ワイス	ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US7700614B2 (en) *	2005-12-14	2010-04-20	Abbott Laboratories	One pot synthesis of tetrazole derivatives of rapamycin
CA2996768C (fr)	2006-04-26	2020-12-08	Micell Technologies, Inc.	Revetements contenant plusieurs medicaments
JP2010500286A (ja) *	2006-07-25	2010-01-07	アボット・ラボラトリーズ	結晶形態のラパマイシン類似体
US7812032B2 (en)	2006-07-25	2010-10-12	Abbott Laboratories	Crystalline forms of rapamycin analogs
US7820812B2 (en)	2006-07-25	2010-10-26	Abbott Laboratories	Methods of manufacturing crystalline forms of rapamycin analogs
CA2679712C (fr)	2007-01-08	2016-11-15	Micell Technologies, Inc.	Stents comportant des couches biodegradables
US11426494B2 (en)	2007-01-08	2022-08-30	MT Acquisition Holdings LLC	Stents having biodegradable layers
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2278966B1 (fr)	2008-03-21	2019-10-09	The University of Chicago	Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
EP2365003A1 (fr)	2008-04-11	2011-09-14	Emergent Product Development Seattle, LLC	Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
SG192523A1 (en)	2008-04-17	2013-08-30	Micell Technologies Inc	Stents having bioabsorbable layers
KR20110020928A (ko)	2008-06-20	2011-03-03	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
EP2313122B1 (fr)	2008-07-17	2019-03-06	Micell Technologies, Inc.	Dispositif médical d administration de médicament
US9510856B2 (en)	2008-07-17	2016-12-06	Micell Technologies, Inc.	Drug delivery medical device
PT2676953T (pt)	2008-12-18	2017-06-29	Novartis Ag	Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CN102256942B (zh)	2008-12-18	2013-07-24	诺瓦提斯公司	1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
CA2747558A1 (fr)	2008-12-18	2010-07-15	Novartis Ag	Nouveaux sels
WO2010120552A2 (fr)	2009-04-01	2010-10-21	Micell Technologies, Inc.	Endoprothèses enduites
WO2010121187A2 (fr)	2009-04-17	2010-10-21	Micell Techologies, Inc.	Endoprothèses vasculaires ayant une élution contrôlée
JP2013501057A (ja)	2009-08-03	2013-01-10	ユニバーシティー・オブ・マイアミ	制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
CA2777128A1 (fr)	2009-10-30	2011-05-05	Ariad Pharmaceuticals, Inc.	Procedes et compositions pour le traitement du cancer
US11369498B2 (en)	2010-02-02	2022-06-28	MT Acquisition Holdings LLC	Stent and stent delivery system with improved deliverability
ES2674745T3 (es) *	2010-02-11	2018-07-03	Bristol-Myers Squibb Company	Macrociclos como inhibidores del factor XIa
CA2797110C (fr)	2010-04-22	2020-07-21	Micell Technologies, Inc.	Endoprotheses et autres dispositifs ayant un revetement de matrice extracellulaire
EP2563391B1 (fr)	2010-04-27	2020-08-26	Roche Glycart AG	Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
CN102234288B (zh) *	2010-05-06	2014-07-02	上海医药工业研究院	唑他莫司的制备方法
EP2593039B1 (fr)	2010-07-16	2022-11-30	Micell Technologies, Inc.	Dispositif médical d'administration de médicament
CA2827673C (fr)	2011-02-18	2020-10-27	Novartis Pharma Ag	Pluritherapie impliquant un inhibiteur de mtor et un inhibiteur de jak
EP2702173A1 (fr)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
US10117972B2 (en)	2011-07-15	2018-11-06	Micell Technologies, Inc.	Drug delivery medical device
KR101937514B1 (ko)	2011-10-14	2019-01-10	브리스톨-마이어스 스큅 컴퍼니	인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
US10188772B2 (en)	2011-10-18	2019-01-29	Micell Technologies, Inc.	Drug delivery medical device
EP2906552B1 (fr)	2012-10-12	2017-11-22	Bristol-Myers Squibb Company	Composés de tetrahydroisoquinoline substitués par guanidine en tant qu'inhibiteurs de factor xia
WO2014059214A1 (fr)	2012-10-12	2014-04-17	Bristol-Myers Squibb Company	Composés de tétrahydroisoquinoléine à substitution guanidine et amine utilisés comme inhibiteurs du facteur xia
TR201807316T4 (tr)	2012-10-12	2018-06-21	Bristol Myers Squibb Co	Bir faktör XIa inhibitörünün kristalli formları.
CA2863243A1 (fr) *	2012-11-30	2014-06-05	Hangzhou Zylox Pharma Co., Ltd.	Analogue de la rapamycine et procedes de fabrication associes
WO2014110258A1 (fr)	2013-01-09	2014-07-17	Podack Eckhard R	Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig
AU2014248508B2 (en)	2013-03-12	2018-11-08	Micell Technologies, Inc.	Bioabsorbable biomedical implants
ES2712699T3 (es)	2013-03-25	2019-05-14	Bristol Myers Squibb Co	Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
WO2014186532A1 (fr)	2013-05-15	2014-11-20	Micell Technologies, Inc.	Implants biomedicaux bioabsorbables
CN105899232A (zh)	2013-11-13	2016-08-24	诺华股份有限公司	用于增强免疫应答的mTOR抑制剂
ES2918501T3 (es)	2013-12-19	2022-07-18	Novartis Ag	Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US10287354B2 (en)	2013-12-20	2019-05-14	Novartis Ag	Regulatable chimeric antigen receptor
CN103739616B (zh) *	2013-12-27	2015-12-30	福建省微生物研究所	含噻唑基雷帕霉素类衍生物及其应用
WO2015108912A1 (fr)	2014-01-16	2015-07-23	MUSC Foundation for Research and Development	Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
NO2760821T3 (fr)	2014-01-31	2018-03-10
CN116987080A (zh)	2014-01-31	2023-11-03	百时美施贵宝公司	作为因子xia抑制剂的具有杂环p2′基团的大环化合物
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
EP3593812A3 (fr)	2014-03-15	2020-05-27	Novartis AG	Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
CA2943609A1 (fr)	2014-03-27	2015-10-01	The Brigham And Women's Hospital, Inc.	Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer
AU2015244039B2 (en)	2014-04-07	2021-10-21	Novartis Ag	Treatment of cancer using anti-CD19 chimeric antigen receptor
MX2016015569A (es)	2014-06-02	2017-04-25	Children´S Medical Center Corp	Metodos y composiciones para inmunomodulacion.
WO2016014530A1 (fr)	2014-07-21	2016-01-28	Novartis Ag	Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
SG10201913765YA (en)	2014-07-21	2020-03-30	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
ES2781175T3 (es)	2014-07-31	2020-08-31	Novartis Ag	Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (fr)	2014-08-14	2016-02-18	Novartis Ag	Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
ES2791248T3 (es)	2014-08-19	2020-11-03	Novartis Ag	Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
CN107074821B (zh)	2014-09-04	2020-05-22	百时美施贵宝公司	为fxia抑制剂的二酰胺大环化合物
KR20250067191A (ko)	2014-09-17	2025-05-14	노파르티스 아게	입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
US9453018B2 (en)	2014-10-01	2016-09-27	Bristol-Myers Squibb Company	Pyrimidinones as factor XIa inhibitors
KR20170068504A (ko)	2014-10-08	2017-06-19	노파르티스 아게	키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
SG11201708516YA (en)	2015-04-17	2017-11-29	David Maxwell Barrett	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (fr)	2015-04-23	2018-02-28	Novartis AG	Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
HK1245095A1 (zh)	2015-05-20	2018-08-24	Novartis Ag	依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
IL258574B2 (en)	2015-11-11	2025-01-01	Novartis Ag	Uses of myostatin antagonists, combinations containing them and their uses
EP3487878A4 (fr)	2016-07-20	2020-03-25	University of Utah Research Foundation	Lymphocytes car-t cd229 et leurs procédés d'utilisation
EP3523331A1 (fr)	2016-10-07	2019-08-14	Novartis AG	Récepteurs antigéniques chimériques pour le traitement du cancer
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2018201056A1 (fr)	2017-04-28	2018-11-01	Novartis Ag	Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
EP3784351A1 (fr)	2018-04-27	2021-03-03	Novartis AG	Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
US20210396739A1 (en)	2018-05-01	2021-12-23	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
JP2022510573A (ja)	2018-07-23	2022-01-27	エンクリアーセラピーズ，インク．	神経障害の治療方法
CN113164557A (zh)	2018-07-23	2021-07-23	因柯利尔疗法公司	治疗神经性病症的方法
JP2022526671A (ja)	2019-04-11	2022-05-25	エンクリアーセラピーズ，インク．	脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
JP2023543868A (ja)	2020-09-29	2023-10-18	エンクリアーセラピーズ，インク．	くも膜下液管理方法およびシステム
EP4240356A1 (fr)	2020-11-03	2023-09-13	RDiscovery, LLC	Thérapies pour le traitement du cancer et de maladies associées à une déficience en phagocytose
CA3223081A1 (fr)	2021-07-15	2023-01-19	Samir Mitragotri	Compositions et methodes associees a des cellules comprenant des particules adherees
CN116082362B (zh) *	2023-01-04	2024-05-10	山东大学	一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995014023A1 (fr) *	1993-11-19	1995-05-26	Abbott Laboratories	Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
WO1998009972A1 (fr) *	1996-09-09	1998-03-12	American Home Products Corporation	Derives de rapamycine presentant une stereochimie non naturelle
CN1235608A (zh) *	1996-09-09	1999-11-17	美国家用产品公司	烷基化的雷帕霉素衍生物

1998
- 1998-09-08 TW TW087114877A patent/TW557297B/zh not_active IP Right Cessation
- 1998-09-23 ZA ZA988750A patent/ZA988750B/xx unknown
- 1998-09-24 PL PL339455A patent/PL191212B1/pl unknown
- 1998-09-24 AT AT98949512T patent/ATE297398T1/de active
- 1998-09-24 DE DE69830502T patent/DE69830502T2/de not_active Expired - Lifetime
- 1998-09-24 KR KR1020077015322A patent/KR100833812B1/ko not_active Expired - Lifetime
- 1998-09-24 KR KR1020067011149A patent/KR100700319B1/ko not_active Expired - Lifetime
- 1998-09-24 WO PCT/US1998/020111 patent/WO1999015530A1/fr not_active Ceased
- 1998-09-24 CZ CZ20001014A patent/CZ299365B6/cs not_active IP Right Cessation
- 1998-09-24 SK SK417-2000A patent/SK285408B6/sk not_active IP Right Cessation
- 1998-09-24 CA CA2303934A patent/CA2303934C/fr not_active Expired - Lifetime
- 1998-09-24 NZ NZ502896A patent/NZ502896A/en not_active IP Right Cessation
- 1998-09-24 NZ NZ514778A patent/NZ514778A/en not_active IP Right Cessation
- 1998-09-24 EP EP98949512A patent/EP1015459B9/fr not_active Expired - Lifetime
- 1998-09-24 DK DK98949512T patent/DK1015459T3/da active
- 1998-09-24 JP JP2000512835A patent/JP3790424B2/ja not_active Expired - Lifetime
- 1998-09-24 CO CO98055672A patent/CO5070656A1/es unknown
- 1998-09-24 IL IL13460798A patent/IL134607A0/xx active IP Right Grant
- 1998-09-24 CN CNB988094223A patent/CN1161360C/zh not_active Expired - Lifetime
- 1998-09-24 BR BR9812305-0A patent/BR9812305A/pt active Search and Examination
- 1998-09-24 KR KR1020007003197A patent/KR100803639B1/ko not_active Expired - Lifetime
- 1998-09-24 AU AU95819/98A patent/AU745576B2/en not_active Expired
- 1998-09-24 SI SI9830781T patent/SI1015459T1/xx unknown
- 1998-09-24 PT PT98949512T patent/PT1015459E/pt unknown
- 1998-09-24 HU HU0004556A patent/HU228368B1/hu unknown
- 1998-09-24 TR TR2000/00778T patent/TR200000778T2/xx unknown
- 1998-09-24 ES ES98949512T patent/ES2244087T3/es not_active Expired - Lifetime
- 1998-09-25 AR ARP980104798A patent/AR015940A1/es active IP Right Grant
2000
- 2000-02-17 IL IL134607A patent/IL134607A/en not_active IP Right Cessation
- 2000-03-20 NO NO20001438A patent/NO325813B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104316A patent/BG64955B1/bg unknown

Also Published As

Publication number	Publication date
CZ20001014A3 (cs)	2000-07-12
IL134607A (en)	2006-04-10
CO5070656A1 (es)	2001-08-28
CA2303934A1 (fr)	1999-04-01
KR100700319B1 (ko)	2007-03-29
DE69830502T2 (de)	2006-05-11
HUP0004556A3 (en)	2001-12-28
KR100803639B1 (ko)	2008-02-19
KR20060071092A (ko)	2006-06-26
TW557297B (en)	2003-10-11
HUP0004556A2 (hu)	2001-10-28
SK4172000A3 (en)	2000-08-14
BG64955B1 (bg)	2006-10-31
ATE297398T1 (de)	2005-06-15
NZ514778A (en)	2005-01-28
CN1271361A (zh)	2000-10-25
ES2244087T3 (es)	2005-12-01
NO325813B1 (no)	2008-07-21
BG104316A (en)	2000-12-29
EP1015459A1 (fr)	2000-07-05
HK1030771A1 (en)	2001-05-18
JP3790424B2 (ja)	2006-06-28
HU228368B1 (en)	2013-03-28
IL134607A0 (en)	2001-04-30
EP1015459B1 (fr)	2005-06-08
SI1015459T1 (en)	2005-10-31
AU745576B2 (en)	2002-03-21
ZA988750B (en)	1999-04-01
NO20001438D0 (no)	2000-03-20
DE69830502D1 (de)	2005-07-14
AU9581998A (en)	1999-04-12
KR20070086925A (ko)	2007-08-27
BR9812305A (pt)	2000-09-05
KR20010024298A (ko)	2001-03-26
PL191212B1 (pl)	2006-03-31
TR200000778T2 (tr)	2000-07-21
NZ502896A (en)	2001-12-21
CA2303934C (fr)	2010-01-26
CN1161360C (zh)	2004-08-11
PT1015459E (pt)	2005-09-30
NO20001438L (no)	2000-05-26
CZ299365B6 (cs)	2008-07-02
KR100833812B1 (ko)	2008-05-30
EP1015459B9 (fr)	2005-10-12
WO1999015530A1 (fr)	1999-04-01
DK1015459T3 (da)	2005-10-10
JP2001517671A (ja)	2001-10-09
PL339455A1 (en)	2000-12-18
AR015940A1 (es)	2001-05-30

Legal Events

Date	Code	Title	Description
2018-11-05	MK4A	Expiry of patent	Expiry date: 20180924

Publication	Publication Date	Title
US6015815A (en)	2000-01-18	Tetrazole-containing rapamycin analogs with shortened half-lives
EP1015459B9 (fr)	2005-10-12	Analogues de rapamycine contenant du tetrazole a demi-vies raccourcies
EP1832592A2 (fr)	2007-09-12	Isomères 15-C de rapamycine et de rapamycine 42-C EPI, leur procédé de fabrication et leur utilisation
EP1826211A1 (fr)	2007-08-29	Isomères et épimères 42 d'analogues alkyl éther de rapmycine, procédés de fabrication et d'utilisation correspondante
EP1829881A1 (fr)	2007-09-05	Combinaison de rapamycine et de ses épimères et isomères de tetrazole, procédés de fabrication et d'utilisation correspondante
EP1826213A1 (fr)	2007-08-29	Analogues de rapamycine contenant une caractéristique antioxydante
EP1826212A1 (fr)	2007-08-29	Isomères et épimères 42 d'analogues d'ester de rapmycine, procédés de fabrication et d'utilisation correspondante
CA2579758A1 (fr)	2007-08-28	Epimeres et isomeres du tetrazole contenant des analogues de rapamycine, et methodes de production et d'utilisation connexes
HK1030771B (en)	2006-04-07	Tetrazole-containing rapamycin analogs with shortened half-lives
MXPA00002976A (en)	2001-07-09	Tetrazole-containing rapamycin analogs with shortened half-lives